Nyxoah SA — Form 6-K Summary
Business Context and Reporting Period
Nyxoah SA furnished this Form 6-K in August 2023 to announce its unaudited financial and operating results for the second quarter and first half of 2023. The filing references a press release dated August 8, 2023 and an H1 2023 report, but the provided filing text contains only the Form 6-K cover information and does not include the exhibits’ underlying results.
Key Financial Metrics
- Revenue, profit, cash flow, margins, debt, and liquidity: The provided filing text does not provide clear values.
- Reporting status: The H1 2023 results were described as unaudited.
- Exhibits: Exhibit 99.1 is the August 8, 2023 press release; Exhibit 99.2 is the H1 2023 report.
Material Changes Versus the Prior Comparable Period
The provided text does not include comparative financial data or a clear description of changes versus the second quarter or first half of 2022.
Guidance, Outlook, Risks, and Unusual Items
The provided cover filing does not state guidance, outlook commentary, specific risks, contingencies, or unusual items. Investors would need to review Exhibits 99.1 and 99.2 for those details.
Investor Verification Checklist
- Verify first-half and second-quarter 2023 revenue, operating loss, net loss, and per-share results.
- Verify cash balance, cash usage, liquidity runway, debt, and financing activities.
- Review operating metrics and any updates concerning Nyxoah’s product commercialization and clinical or regulatory activities.
- Check management’s outlook, guidance, key risks, and any subsequent events described in the H1 2023 report.
- Confirm comparative figures and accounting presentation in the underlying exhibits, which are not included in the provided text.